**Author Information** An event is serious (based on the ICH definition) when the patient outcome is:\* death\* life-threatening\* hospitalisation\* disability\* congenital anomaly\* other medically important event\* Drug interaction

A 29-year-old man developed severe acute respiratory coronavirus 2 (SARS-CoV-2) infection during immunosuppression treatment with ciclosporin, methylprednisolone and mycophenolate-mofetil. He also exhibited increased level of ciclosporin following concomitant administration of ciclosporin and lopinavir/ritonavir.

The man, who had a significant history of arterial hypertension and chronic kidney disease, underwent haemodialysis for 9 months. He underwent a living kidney transplantation on 27 December 2018. He started receiving immunosuppression therapy including mycophenolate-mofetil 0.5g once every 12 hours, ciclosporin \[cyclosporine\] once every 12 hours (75mg every morning and 75mg/100mg alternating every other night) and methylprednisolone 8mg daily. Additionally, his other maintenance treatment included esomeprazole, metoprolol- succinate, aspirin, felodipine, valsartan and diammonium-glycyrrhizinate. On 6 February 2020, he presented to a clinic in China with 2 day history of generalised fatigue and chills and a low-grade fever of 37.7°C. He had no history of contact with other person with similar illness. Subsequent reverse transcription polymerase chain reaction (RT-PCR) assay was negative for SARS-CoV-2. A chest-CT showed bilateral diffuse ground-glass opacity. He started receiving empiric treatment with trimethoprim/sulfamethoxazole for possible*Pneumocystis jirovecii* pneumonia. On 08 February 2020, he was transferred to the other hospital in China due to persistent fatigue and chills and to monitor his renal transplant. Following the admission, he started receiving moxifloxacin in addition to trimethoprim/sulfamethoxazole. At that time, the immunosuppressive regimen and maintenance treatment were continued. After 12 hours of admission, he developed mild chest tightness, nasal stuffiness, loss of appetite, nausea and vomiting. Blood test showed an increased WBC count, hyponatraemia, mild thrombocytopenia and hypoalbuminaemia. Within 24 hours, the RT-PCR test with oropharyngeal swab and sputum was positive for SARS-CoV-2 \[*duration of treatment to reaction onset not stated*\].

The man started receiving off-label treatment with oral lopinavir/ritonavir 1000 mg/day and supportive therapy with unspecified probiotics on hospital day 2 (09 February 2020). The moxifloxacin therapy was stopped. On hospital day 3, he developed dizziness, haematuria, intermittent nausea and vomiting. Blood test showed an increased creatinine and hyponatraemia on that evening. His 24 hour urine volume was low (500mL). He received fluid administration to improve the oliguria and hyponatremia. His 24 hour urine volume on hospital day 4 and day 5 was increased to 2000mL and 2500 mL, respectively. On hospital day 5 (i.e 12 February 2020), a chest CT showed an extensive but slightly improved ground-glass shadowing over both lungs and a strip-like sign over bilateral superior lobes and right lower lobe. His sputum and oropharyngeal swab specimens later found to be negative on RT-PCR for SARS-CoV-2. On hospital day 6, the lopinavir/ritonavir dose was reduced to 750 mg/day and esomeprazole was stopped. He continued to receive immunosuppressive therapy. Blood test showed improved creatinine and hyponatremia. A repeat RT-PCR for SARS-CoV-2 was negative. On hospital day 12 (15 February 2020), chest-CT revealed significant improvement. Blood test were almost normal. On hospital day 13, he was discharged following his recovery from COVID-19. He received treatment with lopinavir/ritonavir for 10 days and with gammaglobulin \[γ--globulin\] for 3 days. The testing of ciclosporin concentration in COVID- 19 patients was not available before 22 February 2020. Therefore, the ciclosporin concentration was tested when he was discharged from the hospital, on stored blood specimens collected on 08 February 2020 and 19 February 2020. The concentration of ciclosporine on fasting specimens (C~0~) was 126.7 ng/mL on 08 February and a concentration of ciclosporine in blood sample collected 2hour after taking the cyclosporine (C~2~) was 1375.6 ng/mL (19 February 2020). The C~0~ was within his usual ciclosporine exposure; however, the C~2~ level after treatment was higher than the C~2~ recommended level, which was considered to be due to interaction between ciclosporin and lopinavir/ritonavir. After 7 day of discharge (i.e. 26 February 2020), at outpatient clinic, his appetite was found to be improved. He had no fever, cough, dyspnoea, nausea, vomiting, headache or diarrhoea. Blood test on 25 February 2020 revealed mild anaemia and hypoalbuminaemia, while creatinine and aminotransferase were slightly increased. Both oropharyngeal swab and sputum were negative for SARS-CoV-2 on RT-PCR on 25 February and 26 February 2020. On 26 February 2020, to confirm the interaction between ciclosporin and lopinavir/ritonavir, C~0~ and C~2~ of ciclosporin were measured. The C~0~ was elevated (260.58 ng/mL) and C~2~ was decreased (319.19 ng/mL), which indicated that the lopinavir/ritonavir might interact via CYP450 with the concentration of ciclosporin even after the discontinuation.
